Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals by Lodi, Sara et al.








Effectiveness of Transmitted Drug Resistance Testing Before Initiation of
Antiretroviral Therapy in HIV-Positive Individuals
Lodi, Sara ; Günthard, Huldrych F ; Gill, John ; Phillips, Andrew N ; Dunn, David ; Vu, Quang ;
Siemieniuk, Reed ; Garcia, Federico ; Logan, Roger ; Jose, Sophie ; Bucher, Heiner C ; Scherrer,
Alexandra U ; et al
Abstract: BACKGROUND For people living with HIV, major guidelines in high-income countries rec-
ommend testing for transmitted drug resistance (TDR) to guide the choice of first-line antiretroviral
therapy (ART). However, individuals who fail a first-line regimen can now be switched to one of several
effective regimens. Therefore, the virological and clinical benefit of TDR testing needs to be evaluated.
METHODS We included individuals from the HIV-CAUSAL Collaboration who enrolled <6 months of
HIV diagnosis between 2006 and 2015, were ART-naive, and had measured CD4 count and HIV-RNA.
Follow-up started at the date when all inclusion criteria were first met (baseline). We compared 2 strate-
gies: (1) TDR testing within 3 months of baseline versus (2) no TDR testing. We used inverse probability
weighting to estimate the 5-year proportion and hazard ratios (HRs) of virological suppression (confirmed
HIV-RNA <50 copies/mL), and of AIDS or death under both strategies. RESULTS Of 25,672 eligible
individuals (82% males, 52% diagnosed in 2010 or later), 17,189 (67%) were tested for TDR within 3
months of baseline. Of these, 6% had intermediate- or high-level TDR to any antiretroviral drug. The
estimated 5-year proportion virologically suppressed was 77% under TDR testing and 74% under no TDR
testing; HR 1.06 (95% confidence interval: 1.03 to 1.19). The estimated 5-year risk of AIDS or death
was 6% under both strategies; HR 1.03 (95% confidence interval: 0.95 to 1.12). CONCLUSIONS TDR
prevalence was low. Although TDR testing improved virological response, we found no evidence that it
reduced the incidence of AIDS or death in first 5 years after diagnosis.
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Background: For people living with HIV, major guidelines in
high-income countries recommend testing for transmitted drug
resistance (TDR) to guide the choice of first-line antiretroviral
therapy (ART). However, individuals who fail a first-line regimen
can now be switched to one of several effective regimens. Therefore,
the virological and clinical benefit of TDR testing needs to
be evaluated.
Methods: We included individuals from the HIV-CAUSAL
Collaboration who enrolled ,6 months of HIV diagnosis between
2006 and 2015, were ART-naive, and had measured CD4 count
and HIV-RNA. Follow-up started at the date when all inclusion
criteria were first met (baseline). We compared 2 strategies: (1)
TDR testing within 3 months of baseline versus (2) no TDR testing.
We used inverse probability weighting to estimate the 5-year
proportion and hazard ratios (HRs) of virological suppression
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(confirmed HIV-RNA ,50 copies/mL), and of AIDS or death
under both strategies.
Results: Of 25,672 eligible individuals (82% males, 52% diag-
nosed in 2010 or later), 17,189 (67%) were tested for TDR within 3
months of baseline. Of these, 6% had intermediate- or high-level
TDR to any antiretroviral drug. The estimated 5-year proportion
virologically suppressed was 77% under TDR testing and 74% under
no TDR testing; HR 1.06 (95% confidence interval: 1.03 to 1.19).
The estimated 5-year risk of AIDS or death was 6% under both
strategies; HR 1.03 (95% confidence interval: 0.95 to 1.12).
Conclusions: TDR prevalence was low. Although TDR testing
improved virological response, we found no evidence that it reduced
the incidence of AIDS or death in first 5 years after diagnosis.
Key Words: transmitted drug resistance, antiretroviral therapy,
genotypic testing
(J Acquir Immune Defic Syndr 2019;82:314–320)
INTRODUCTION
Transmitted drug resistance (TDR) occurs when an
individual is infected with a strain of HIV that is resistant to
a single antiretroviral, an entire drug class, or multiple classes.
The prevalence of TDR in ART-naive individuals in high-
income countries ranges between 7% and 14%.1–7 Clinical
practice guidelines recommend TDR testing—a genotypic
test— in all individuals newly diagnosed with HIV before
initiating antiretroviral therapy (ART).8–11 The expectation is
that TDR test results will guide the choice of ART agents and
reduce the risk of using a less effective regimen. Use of a drug
to which the virus is resistant could be detrimental in the long
term because it prolongs the time to achieve virological
suppression and increases the risk of developing resistance to
active treatments.12–15
Although TDR testing was shown to be beneficial in the
early 2000s16 rapid changes in the landscape of HIV
treatment require a reevaluation of the value of TDR testing.
Treatments containing agents with a high barrier to resistance,
such as integrase inhibitors and boosted darunavir, as well as
several other potent second- and third-line ART options are
now widely available in high-income settings. These innova-
tions imply that although most individuals will achieve
adequate virological suppression from their initial regimen,
those who do not will likely do so after switching to an
alternative treatment.
Here, we used observational data to estimate the
effectiveness of TDR testing, when used according to current
guidelines, on virological and clinical outcomes up to 5 years
after HIV diagnosis among individuals diagnosed with HIV
in Europe and Canada between 2006 and 2015.
METHODS
Study Data
The HIV-CAUSAL Collaboration is a consortium of
prospective HIV cohorts from Europe and the Americas. All
cohorts recorded routinely collected data in clinical practice
within settings with universal access to care. Data collected
include patient characteristics (age, sex, geographical origin,
and transmission category), use of ART (type of regimes and
dates of start and stop), CD4 cell counts, and plasma HIV-
RNA, AIDS-defining conditions, and death (cause(s) and
date). Each cohort submits data in a standardized format
(http://www.hicdep.org/) to the coordinating center. The
analyses presented here are based on data pooled from 7
cohorts within the HIV-CAUSAL Collaboration that contrib-
uted data on genotypic drug resistance testing conducted as
part of routine clinical care: AMACS (Greece), ATHENA
(Netherlands), CoRIS (Spain), Swiss HIV Cohort Study
(Switzerland), the South Alberta Cohort Study (Canada),
UK CHIC/UK HIV Drug Resistance Database (United
Kingdom), and UK Register of HIV Seroconverters (United
Kingdom). The date of a TDR testing was the date the blood
sample for the testing was drawn, rather than the date
of sequencing.
We defined a TDR test as any genotypic drug resistance
test conducted while the individual was ART-naive. Predicted
resistance was derived for all individuals using the Genotypic
Resistance Interpretation Algorithm, version 7.0 (HIVdb
Program, Stanford University, http://hivdb.stanford.edu).
TDR was defined as predicted intermediate- or high-level
resistance to any of the following antiretroviral drugs in use
during the study period: atazanavir, darunavir, fosamprenavir,
indinavir, lopinavir, nelfinavir, saquinavir, tipranavir [pro-
tease inhibitors (PIs)]; lamivudine, emtricitabine, abacavir,
didanosine, tenofovir, stavudine, zidovudine [nucleoside
reverse transcriptase inhibitors (NRTIs)]; nevirapine, efavir-
enz, etravirine, rilpivirine [nonnucleoside reverse transcrip-
tase inhibitors (NNRTIs)]. Resistance to integrase inhibitors,
fusion inhibitors, and CCR antagonists were not routinely
measured in the participant cohorts. Resistance data on
integrase inhibitors were collected in only one cohort and
were rare even in this cohort.17
The date of ART initiation was the date that a patient
initiated HIV treatment including at least 2 NRTIs plus one or
more of the following: an integrase inhibitor, PIs, an NNRTI,
an entry inhibitor, or a fusion inhibitor. Regimens consisting
of abacavir or tenofovir with 2 or more additional nucleoside
transcriptase inhibitors were also considered ART regimens,
but they were rare in our population (,2%).
Eligibility Criteria
The analyses were restricted to individuals who met the
following eligibility criteria between January 1, 2006, and
December 31, 2015: aged 18 years and older, CD4 cell count
and HIV-RNA measurements within 3 months of each other
while ART-naive, and less than 6 months since HIV
diagnosis. We restricted the analysis to individuals enrolled
in clinics within cohorts where at least 30% of patients had
received a genotypic drug resistance test while naive.
TDR Testing Strategies
We compared the following 2 strategies: (1) TDR
testing under current recommendations, defined as genotypic
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drug resistance testing within 3 months while ART-naive, and
(2) no TDR testing, defined as no genotypic drug resistance
before receiving ART. The 3-month time window for testing
(the “grace period”) corresponds to the period within which
90% of TDR testing took place in our data. Note that our
analysis emulates a pragmatic trial to estimate the effective-
ness of TDR testing in which decisions concerning ART
initiation are left to the discretion of the treating physicians.
For descriptive purposes, we compared the proportion of
individuals who initiated ART under the 2 strategies.
Outcomes
We considered the following 2 outcomes: (1) virolog-
ical suppression, defined as the second of 2 consecutive HIV-
RNA,50 copies/mL after initiating ART, and (2) a combined
endpoint of an AIDS-defining condition18 or death. Sepa-
rately for each outcome, we computed the 5-year cumulative
incidence under each strategy, the difference in cumulative
incidence, and the hazard ratio (HR).
Follow-up
For each individual, follow-up started at baseline,
defined as the earliest date that all eligibility criteria were
met, and ended at the earliest of developing the outcome, 12
months after the most recent HIV-RNA or CD4 count
measurement (censoring due to infrequent laboratory meas-
urements), cohort-specific administrative end of follow-up
(ranging from December 2013 to November 2015), date of
pregnancy when known, or initiation of an ART combination
not defined as ART.
Statistical Analyses
For each outcome, we estimated the HR of TDR testing
versus no testing using a pooled logistic regression model
with an indicator for TDR testing strategy, month of follow-
up (restricted cubic splines with 4 knots), and the following
covariates at baseline: cohort, sex, HIV acquisition group
(heterosexual contact, homosexual contact, or bisexual con-
tact, injecting drug use, or other/unknown), geographical
origin (Western countries, sub-Saharan Africa, other,
unknown), age (,35, 35–50, .50 years), HIV-RNA (,4,
4–5,.5 log10 copies/mL), CD4 cell count strata (,100–199,
200–349, 350–499, $500 cells/mm3), AIDS, and calendar
year (2006–2009, 2010–2015) at HIV diagnosis. In the model
for the virological outcome, we considered death as a cen-
soring event. We also fit pooled logistic regression models for
each outcome like the one described above and added an
interaction term between month and the indicator of TDR
testing strategy. The model’s predicted probabilities were
then used to estimate the 5-year cumulative incidence under
each strategy and the difference in these values.
TDR testing strategies are defined over a 3-month grace
period. For individuals who were not tested for TDR in the
baseline month, TDR testing is a postbaseline variable.19
Therefore, to avoid immortal time bias, we replaced each
individual without a TDR test in the baseline month by 2
identical clones.20–22 The first clone was assigned to the TDR
testing strategy and was censored on deviation from that
strategy, that is, at 3 months if the individual had not received
a TDR test by that time, or earlier at the time of ART
initiation, if the individual initiated ART before receiving
a TDR test during the grace period. The second clone was
assigned to the no TDR testing strategy and was censored on
deviation from that strategy, that is, when the individual
received a TDR test. Examples of how cloning and artificial
censoring occurred under each TDR testing strategy are
presented in Appendix Figure 1, Supplemental Digital
Content, http://links.lww.com/QAI/B368.
To adjust for the potential selection bias induced by
censoring, we weighted each clone at each time by the inverse
of the probability of remaining uncensored.21 To estimate the
weights for censoring due to deviation from the assigned
TDR testing strategy, we fit 2 separate pooled logistic
regression models for ART initiation before TDR testing
and for TDR testing while ART-naive in the original data set.
Each model included the previously listed covariates plus the
most recent CD4 cell count (restricted cubic splines with
knots at 200, 350, 500 and 1000 cells/mm3), HIV-RNA
category (,1000, 1000–10,000, .100,000 copies/mL), diag-
nosis of AIDS (when the outcome was virological suppres-
sion), and months since the last CD4 and last HIV-RNA
measurements. Individuals who had TDR testing at baseline
month were assigned a weight equal to 1. To estimate weights
for censoring due to infrequent laboratory measurements, we
used a pooled logistic regression model with the same
covariates as in the models listed above on the original data
set. We stabilized and multiplied the 2 sets of weights.23,24
The mean of the weights was 1.02 (min 0.20, max 7.8).
Estimates of the effect of TDR testing remained basically
unchanged in analyses with weights truncated at the
99th percentile.
We used a nonparametric bootstrap procedure based on
500 samples to obtain percentile-based 95% confidence
intervals (CIs). All analyses were conducted with SAS
version 9.4.
Sensitivity Analyses
We conducted several sensitivity analyses to examine
the robustness of our findings. First, because the proportion
of individuals tested for TDR varied by center and cohort,
we restricted the analyses to (1) the 3 cohorts with highest
overall occurrence of TDR testing (UK CHIC/UK Drug
Resistance Database, Swiss HIV Cohort Study and South-
ern Alberta Cohort) and (2) centers in each cohort where at
least 50% of patients were tested for TDR. Second, because
some TDR may revert relatively quickly after infection in
the absence of therapy (eg, 184V, and K65R),25 false-
negative tests might occur for individuals who had been
infected with HIV for many years. We, therefore, repeated
the analyses on the subset of individuals with early HIV
disease defined as having a CD4 count . 500 cells/mm3 at
baseline. Third, to account for changes over time of
antiretroviral combinations, we repeated the analysis
separately by calendar period (2006–2009 versus
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2010–2015). Fourth, because some TDR tests might have
been conducted retrospectively on previously collected
blood samples, we reran the analyses excluding individuals
who initiated an ART combination including a treatment to
which they were resistant. Fifth, we restricted the analyses
to homosexual or bisexual males, the group with the
highest prevalence of TDR testing and TDR detection in
our data. Sixth, ART initiation might be prioritized over
TDR testing in individuals with more advanced HIV
disease such as late presenters. We, therefore, rerun the
analyses changing the definition of TDR testing by
allowing genotypic tests occurring within 2 weeks after
ART initiation. Because individuals with late diagnosis are
at risk of early virological failure and possibly faster
clinical progression, we restricted the analyses to individ-
uals with late HIV diagnosis defined as having a CD4
,200 cells/mm3 or AIDS at baseline and to individuals
with advanced HIV disease, defined as having a CD4 ,200
cells/mm3 or AIDS at baseline.26 Finally, in the analyses
where virological suppression was an outcome, death was
treated as a competing risk rather than a censoring event.
RESULTS
Of 25,672 eligible individuals, 82% were men, 44%
were late HIV presenters, and 52% started follow-up in 2010
or later. Their median [interquartile range (IQR)] CD4 cell
count, HIV-RNA, and age at baseline were 390 (221–570)
cells/mm3, 4.6 (4.0–5.2) log10 copies/mL, and 36 (29–44)
years, respectively (Table 1). A total of 16,354 (64%)
individuals initiated ART at a median (IQR) CD4 cell count
of 276 (160–383) cells/mm3. Of these, 9953 (61%) started
with an NNRTI regime, 5384 (33%) with a boosted PI
regime, 778 (5%) with an INSTI regime, 228 (1%) with an
unboosted PI regime, and 11 (,1%) with a 3 NRTI regime.
TDR testing while ART-naive occurred in 67% of
individuals within 3 months of baseline (91% of them during
the baseline month). Median (IQR) follow-up was 31 (14–58)
and 24 (11–49) months for individuals with TDR testing and
no TDR testing, respectively. Of 17,189 individuals with
TDR testing, 5.8% had TDR to any antiretroviral drug, 1.2%
to any PI, 3.7% to any NNRTI, and 1.7% to any NRTI. The
most commonly detected TDR to individual drugs were to
nevirapine (3.5%), efavirenz (3.0%), and stavudine (1.3%).








CD4 count, cells/mm3 ,100 3094 (12) 34 (14–62) 1937 (64) 104 (5)
100–200 2542 (10) 33 (14–60) 1686 (66) 82 (5)
200–349 5421 (21) 31 (13–59) 3803 (70) 206 (5)
350–499 5961 (23) 27 (13–53) 4106 (69) 255 (6)
$500 8654 (34) 25 (11–50) 5657 (65) 352 (6)
HIV-RNA, copies/mL ,10,000 6231 (24) 28 (12–55) 3880 (62) 238 (6)
10,000–100,000 10,984 (43) 28 (13–55) 7560 (69) 455 (6)
100,000 8457 (33) 29 (13–55) 5749 (68) 306 (5)
Sex Male 21,101 (82) 29 (13–56) 14,358 (68) 847 (6)
Female 4571 (18) 27 (11–53) 2831 (62) 152 (5)
HIV acquisition group Heterosexual contact 7713 (30) 29 (13–57) 4863 (63) 261 (5)
Homosexual contact 15,429 (60) 29 (14–56) 10,765 (70) 652 (6)
Injecting drug use 719 (3) 18 (11–38) 431 (60) 16 (4)
Other/unknown 1811 (7) 23 (11–50) 1130 (68) 70 (6)
Geographical origin Western countries 10,430 (41) 33 (14–62) 6340 (61) 405 (6)
Sub-Saharan Africa 1133 (4) 30 (12–62) 666 (59) 33 (5)
Rest of the world 2470 (10) 28 (11–53) 1362 (55) 79 (6)
Unknown country 11,639 (45) 25 (12–49) 8821 (76) 482 (5)
Calendar year 2006–2009 12,249 (48) 56 (24–75) 8334 (68) 484 (6)
2010–2015 13,423 (52) 19 (11–32) 8855 (66) 515 (6)
Age, yr ,35 11,921 (46) 25 (12–50) 8087 (68) 451 (6)
35–49 10,651 (41) 32 (14–59) 7131 (67) 423 (6)
.50 3100 (12) 31 (14–58) 1971 (64) 125 (6)
Late HIV presentation No 14,257 (56) 26 (12–51) 9513 (67) 595 (6)
Yes 11,415 (44) 32 (14–60) 7676 (67) 404 (5)
All 25,672 (100) 28 (13–55) 17,189 (100) 999 (100)
*TDR test = genotypic HIV resistance test within 3 months of baseline in an ART-naive patient.
†Proportions with TDR among individuals who were tested.
MSM, men who have sex with men; MSW, men who have sex with women.
Effectiveness of TDR TestingJ Acquir Immune Defic Syndr  Volume 82, Number 3, November 1, 2019
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. www.jaids.com | 317
Of those with a detected TDR, 5% initiated ART with
a combination containing a drug to which they were resistant.
The proportion of individuals with a detected TDR varied by
cohort but was similar across subgroups defined by late HIV
presentation status, sex, age, calendar year, CD4 count, and
HIV-RNA at baseline (last column, Table 1). Detected TDR
was less common among injecting drug users than in other
HIV acquisition groups.
Figure 1 and Appendix Figure 2, Supplemental Digital
Content, http://links.lww.com/QAI/B368, show the cumula-
tive incidence curves under the 2 TDR testing strategies
assuming no informative loss to follow-up. As shown in
Table 2, the estimated 5-year risk (95% CI) of AIDS or death
was 6.0% (5.6 to 6.4) under TDR testing and 5.7% (5.1 to
6.4) under no TDR testing; difference 0.30% (20.30 to 0.94);
HR 1.03 (0.95 to 1.12).
The estimated 5-year proportion (95% CI) who
achieved virological suppression was 77.4% (76.6 to 78.2)
under TDR testing and 73.7% (72.0 to 75.4) under no TDR
testing; difference 3.7% (2.1 to 5.3); HR 1.06 (1.03 to 1.09).
The estimated proportion (95% CI) of individuals who had
ever initiated ART by 5 years of baseline was 87% (85 to 88)
under TDR testing and 87% (83 to 90) under no TDR testing.
The results of the sensitivity analyses are presented in
Table 3. The results did not materially change when the
analyses were restricted to individuals from the 3 cohorts with
the highest rate of TDR testing, to those who were enrolled in
centers with more than 50% TDR testing, to individuals with
late HIV diagnosis, or to homosexual or bisexual males; when
excluding individuals who initiated ART with a combination
containing a drug to which they were resistant; or when death
was considered as a competing risk. The estimated HRs of
virological suppression for TDR testing versus no TDR
testing were similar for individuals with baseline in the
period 2005–2010 and 2011–2015.
DISCUSSION
In individuals diagnosed with HIV in high-income
countries, we estimated that current recommendations for
TDR testing, compared with no TDR testing, increased the
proportion achieving virological suppression by 5 years from
diagnosis by 3.7% but with no effect on AIDS or death in this
time frame.
One explanation for the lack of any short-term clinical
benefit is the low prevalence of TDR (approximately 6% in
our population), which imposes a hard limit on the maximum
gain that can be achieved by TDR testing. As TDR testing
may be beneficial in populations with higher TDR prevalence,
care should be taken with extrapolating our results to
resource-limited settings because of the differences in the
TDR prevalence, HIV subtypes, CD4 count distribution at
HIV diagnosis, and treatment patterns. Also, there may be
other benefits of TDR testing that our study could not
quantify, including some decrease in HIV transmission
because of a modest increase in virological suppression,27,28
and the generation of genotypic information to describe the
dynamics of local HIV transmission (through phylogenetic
tree studies) and the changing patterns of drug resistance.29–34
Previous studies have compared the virological
response after ART initiation for individuals with and without
a previously detected TDR.12–15 However, this approach
might lead to selection bias if TDR testing affects the
likelihood of ART initiation or loss to follow-up. Unlike
these studies, we estimated the effect of TDR testing rather
than of having a detected TDR. Importantly, we quantified the
risk of the virological and clinical outcomes since baseline,
a proxy of entry into HIV care and thus of the recommended
time for testing, rather than since ART initiation. In fact, our
approach parallels the design and emulation of a pragmatic
randomized trial of TDR testing in which individuals are
randomly assigned to either TDR testing or no testing while
not intervening on other aspects of their care. Another
strength of our study is the large sample size of over
FIGURE 1. Cumulative incidence of AIDS or death by TDR
testing strategy, HIV-CAUSAL Collaboration 2006–2015.
TABLE 2. Five-Year Estimated Cumulative Incidence (95% CI) of Virological and Clinical Outcomes Under TDR Testing and No




5-Year Difference in Cumulative
Incidence (95% CI) HR (95% CI)
Virological success (N = 25,672) TDR testing 77.4% (76.6 to 78.2) 3.7 (2.1 to 5.3) 1.06 (1.03 to 1.09)
No TDR testing 73.7% (72.0 to 75.4) 0 (ref) 1 (ref)
AIDS or death (N = 23,728) TDR testing 6.0% (5.6 to 6.4) 0.3% (20.3 to 0.9) 1.03 (0.95 to 1.12)
No TDR testing 5.7% (5.1 to 6.4) 0 (ref) 1 (ref)
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25,000 individuals and the setting in HIV clinics in Europe
and Canada that are considered representative of routine
clinical practice where TDR testing is part of routine clinical
routine.35
TDR testing is controversial in individuals who
present for HIV care with advanced immunosuppression
and are therefore in need of immediate initiation of
effective treatment.36,37 Although TDR testing might be
beneficial to identify the optimal treatment combination in
a population with high mortality, it might also cause delays
in initiating treatment and most clinicians would not want
to wait for the result of the resistance test before initiating
ART.38 Also, because of the availability of several
effective second-line options, patients who do not respond
have the opportunity to be switched to an effective drug
and virological suppression may end up being delayed only
by a few months. A large proportion of patients in our
population (44%) presented late for HIV diagnosis. We
found that the HRs of both the clinical and virological
outcomes in the subset of individuals with late HIV
diagnosis or advanced HIV disease at baseline were similar
to the one in the overall population. This supports current
TDR testing recommendations that do not vary by HIV
presentation status.
Current guidelines worldwide recommend ART initia-
tion with integrase inhibitors.39–42 Only a small proportion of
patients (5%) in our study initiated treatment with integrase
inhibitors; so, we could not appropriately assess TDR for this
drug class, which seems to be rare at this point.11,17,43 In
high-income countries, it is common practice not to delay
ART initiation until the results of the drug resistance test
become available, which usually takes 2 weeks.10 Instead,
because resistance can emerge quickly in low-resistance
barrier containing drugs,11 when an NNRTI-based
regimen is considered as first-line treatment, the results
of the resistance test should be available before
starting treatment.
Our study has several limitations. First, the validity of
our estimates relies on the untestable assumption that all
confounders were adequately adjusted for. We expect this
assumption to approximately hold because we adjusted for
the most important known predictors for TDR including risk
group, sex, and calendar year. Second, some TDR tests could
have been performed retrospectively on stored blood samples,
possibly in response to virological failure in individuals
believed to have good adherence, which might have intro-
duced bias. However, this is unlikely to have affected our
estimates because only 5% of patients with a TDR test started
with a combination containing an ART they were resistant to.
Third, 5 years might not be a long enough period to examine
differences in clinical outcomes. Finally, although TDR
testing was recommended in all countries of the study
between 2006 and 2015,44–47 the large proportion of individ-
uals who were not tested (33%) might reflect incomplete data.
The robustness of our results to sensitivity analyses restricting
to centers with more than 50% patients tested for TDR and to
cohorts with high TDR testing uptake is reassuring.
In conclusion, we found a low prevalence of TDR in
high-income countries. Although TDR testing seems to
improve virological suppression after ART initiation, we
found no evidence that it reduced the incidence of AIDS or
death for up to 5 years after baseline. These results call for
more evidence to establish which populations would benefit
from selective TDR screening.
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